TrueNorth Inc. boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 5.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,173 shares of the life sciences company’s stock after purchasing an additional 637 shares during the period. Illumina comprises approximately 1.2% of TrueNorth Inc.’s holdings, making the stock its 22nd largest position. TrueNorth Inc.’s holdings in Illumina were worth $2,624,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. First Citizens Bank & Trust Co. grew its stake in shares of Illumina by 0.4% during the 2nd quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after buying an additional 12 shares during the period. Patten Group Inc. lifted its holdings in Illumina by 2.7% in the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares in the last quarter. Puzo Michael J lifted its holdings in Illumina by 0.4% in the 2nd quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock worth $1,032,000 after buying an additional 25 shares in the last quarter. Flagship Harbor Advisors LLC lifted its holdings in Illumina by 1.7% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock worth $345,000 after buying an additional 35 shares in the last quarter. Finally, Eqis Capital Management Inc. lifted its holdings in Illumina by 0.6% in the 2nd quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock worth $1,200,000 after buying an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 93.07% of the company’s stock.
In other Illumina news, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the completion of the sale, the senior vice president now owns 24,908 shares of the company’s stock, valued at approximately $5,263,807.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $210.59, for a total transaction of $4,211,800.00. Following the sale, the director now directly owns 536,717 shares of the company’s stock, valued at approximately $113,027,233.03. The disclosure for this sale can be found here. Insiders sold 187,964 shares of company stock valued at $38,454,069 in the last three months. Company insiders own 1.60% of the company’s stock.
Illumina, Inc. (NASDAQ:ILMN) opened at $208.94 on Friday. Illumina, Inc. has a fifty-two week low of $119.37 and a fifty-two week high of $214.50. The company has a market cap of $30,603.06, a price-to-earnings ratio of 61.29, a price-to-earnings-growth ratio of 3.46 and a beta of 0.74. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. Illumina’s revenue was up 17.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.97 earnings per share. equities research analysts predict that Illumina, Inc. will post 3.75 EPS for the current year.
A number of brokerages have recently issued reports on ILMN. Barclays PLC restated an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a research note on Wednesday, August 9th. Vetr raised shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 price objective for the company in a research report on Wednesday, August 9th. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. Cowen and Company reiterated an “outperform” rating and issued a $200.00 price objective on shares of Illumina in a report on Wednesday, August 2nd. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $200.00 target price on shares of Illumina in a research note on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $200.88.
ILLEGAL ACTIVITY NOTICE: “Illumina, Inc. (NASDAQ:ILMN) Stake Lifted by TrueNorth Inc.” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/illumina-inc-ilmn-holdings-raised-by-truenorth-inc.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.